Activity of nadifloxacin and three other antimicrobial agents against Cutibacterium acnes isolated from patients with acne vulgaris

Nadifloxacin (OPC-7251) represents an established antimicrobial agent belonging to the quinolone group and was developed exclusively for topical administration. Nadifloxacin is effective in treating a variety of bacterial skin infections and acne. Here, the in vitro activity of nadifloxacin was assessed and compared with those of erythromycin, clindamycin and tetracycline against Cutibacterium (C.) acnes, formerly Propionibacterium acnes, to gain a picture of the resistance situation in Germany. The study was approved by the Ethics Committee of the Bayerische Landesärztekammer (Munich, Germany; EC-No.17088) and registered at Deutsches Register Klinische Studien (ID:DRKS00014231).